You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Leading medical-scientific event on Hemophilia held in Trieste, Italy

Kedrion-organized congress put replacement therapy, personalization and access to care in the spotlight

read more 

EVENTS

Kedrion scientific symposium at the 2019 PNS Conference in Genoa, Italy

A chance for world Key Opinion Leaders to debate possible new therapies for the treatment of CIPN

read more 

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 
  1. EVENTS - 23-09-2016

    Pharmaceutical digitization: how to improve patient care and engagement

    Kedrion Biopharma Advisor Prof. Albert Farrugia lectures at "The Future of Science" Conference in Venice, Italy

    read more 
  2. PLASMA & BIOTHERAPIES - 16-09-2016

    Humanitarian Factor IX donation to Afghanistan

    Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries

    read more 
  3. PLASMA & BIOTHERAPIES - 13-09-2016

    Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment

    BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017

    read more 
  4. EVENTS - 26-07-2016

    SIPPET Study was WHF 2016 World Congress highlight

    A Kedrion, Grifols and LFB supported symposium featured a lecture by Dr. Manuel Carcao

    read more 

Pages

For more information please contact: pressoffice@kedrion.com